ロード中...
HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B- and T-cell lines
BACKGROUND: HDAC inhibitors (HDACi) belong to a new group of chemotherapeutics that are increasingly used in the treatment of lymphocyte-derived malignancies, but their mechanisms of action remain poorly understood. Here we aimed to identify novel protein targets of HDACi in B- and T-lymphoma cell l...
保存先:
| 出版年: | J Transl Med |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7137348/ https://ncbi.nlm.nih.gov/pubmed/32264925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02318-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|